Klive Tablet contains a combination of L-Ornithine L-Aspartate (150 mg) and Pancreatin (100 mg), formulated to support liver function and enhance digestive enzyme activity. L-Ornithine L-Aspartate is an amino acid compound that plays a crucial role in ammonia detoxification by promoting the urea cycle, thereby aiding in the reduction of elevated blood ammonia levels commonly observed in hepatic encephalopathy and other liver dysfunctions. Pancreatin is a mixture of digestive enzymes including amylase, lipase, and protease, which facilitate the breakdown of carbohydrates, fats, and proteins, improving nutrient absorption in patients with pancreatic insufficiency or digestive disorders. Klive Tablet is indicated for the management of chronic liver diseases, hepatic encephalopathy, and exocrine pancreatic insufficiency, providing symptomatic relief and supporting metabolic functions. The combination therapy helps restore normal metabolic processes, reduce symptoms such as fatigue and digestive discomfort, and improve overall patient outcomes. Klive Tablet should be administered under medical supervision, with dosage adjusted according to the severity of the condition and patient response. Contraindications include hypersensitivity to any component and acute pancreatitis. Adverse effects are generally mild but may include gastrointestinal disturbances. Regular monitoring of liver function tests is recommended during prolonged use.